Over 150 companies would benefit from new FDA decision on US user fee relief
This article was originally published in Clinica
FDA officials expect to see a $13.3m decline in device user fee collections over the next two years if Congress enacts legislation that stabilises fee increases and raises the threshold for companies to qualify for the lower fees charged to small business.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.